Echo IQ Secures Exclusive Advara Data Licence to Expand Cardiovascular AI Platform

Echo IQ (ASX: EIQ) has executed a definitive exclusive data licensing agreement with Advara HeartCare that could provide access to up to 1 million de-identified echocardiography studies for future cardiovascular AI product development.

The agreement gives Echo IQ access to one of Australia’s largest private cardiovascular imaging datasets, including echocardiographic images and associated clinical information across a broad patient population.

Advara operates Australia’s largest private cardiovascular diagnostics network, supporting more than 750,000 patient interactions each year across cardiology clinics, diagnostic services, clinical research, and data-driven innovation.

Echo IQ—which will retain ownership of all AI outputs generated from the licensed data under the intellectual property protections built into the agreement—expects the dataset to strengthen future EchoSolv development, training, and validation activity across next-generation cardiovascular AI products.

The agreement has an initial three-year term and an option to extend for a further three years, with initial delivery of licensed data subject to Human Research Ethics Committee (HREC) approval and agreement between the parties on data quality specifications.

Exclusive Data Access

The agreement covers an expected dataset of between 500,000 and 1 million de-identified echocardiography studies, and includes binding exclusivity provisions, data quality and de-identification standards, confidentiality obligations, and data security requirements.

The dataset will give Echo IQ access to echocardiographic images, associated clinical datasets and linked information such as de-identified patient demographics, referral pathways, diagnostic findings, and relevant clinical outcomes where applicable.

Echo IQ expects large-scale imaging data to become increasingly important as cardiovascular AI shifts beyond single-disease applications toward broader multi-condition diagnostic and predictive platforms, and considers the Advara dataset highly complementary to its existing relationship with the National Echo Database Australia (NEDA).

NEDA provides longitudinal cardiovascular outcomes data for clinical validation, evidence generation, and regulatory strategy, while Advara provides real-world imaging data suited to AI development and model training.

The final dataset size remains subject to extraction, matching, de-identification, and quality review, with Advara guaranteeing delivery of at least 500,000 de-identified echocardiograms and at least 70% of licensed data meeting agreed quality specifications.

Large-Scale Real-World Imaging

Echo IQ chief executive officer Dustin Haines said securing access to a dataset of this scale was strategically important for the company.

“While NEDA continues to provide a world-class platform for clinical validation and outcomes research, the Advara dataset brings something different and highly complementary, which centres around large-scale real-world imaging data that can be used to train, refine and develop future generations of cardiovascular AI products,” he added.

Advara chief executive officer Dr David O’Donnell said the collaboration aligned with the group’s primary focus.

“At Advara, we are focused on continuing to provide world leading care to our patients, and we see that AI has the potential to complement the role of the clinician in providing this best quality care to our patients,” he said.

“We are pleased to collaborate with Echo IQ in supporting the development of next-generation AI-enabled cardiovascular imaging applications.”